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Effects of long and short hemodialysis on endothelial function: The vascular endothelium plays a fundamental role
A short-term study. in the regulation of cardiovascular function [1]. When
Background. Endothelial dysfunction is common in end- endothelial function is disturbed, its ability to protect thestage renal disease and may contribute to the development of
blood vessel by modulating vascular tone and interactingboth hypertension and atherosclerosis. Long-slow hemodialysis
with blood components is impaired, leaving it susceptible(HD) has been associated with superior blood pressure control
and fewer cardiovascular complications. We hypothesized that to the development of atherosclerosis. Patients with
long dialysis times would improve endothelial function com- chronic renal failure frequently have endothelial dys-
pared with shorter dialysis times. function and are at a greatly increased risk of developingMethod. Eight long-term hemodialysis patients, not on anti-
atherosclerosis. Factors known to impair endothelialhypertensive drugs and with no evidence of vascular disease,
function that are common in uremia include lipid abnor-were studied in a three-way randomized crossover-controlled
trial. Each received, for one week and in randomized sequence, malities, hyperhomocysteinemia [2, 3] and the accumula-
four hours of HD (SD), eight hours of HD, and eight hours of tion of inhibitors of nitric oxide synthesis [4].
HD using a smaller dialyzer and slower blood pump. The same Endothelial dysfunction may be detectable long be-post-dialysis target weights were used with each treatment. On
fore the development of symptomatic atherosclerosis [5].the third day of each treatment endothelium-dependent (flow
A number of tests exist for assessing various aspects ofmediated) and independent glyceryl trinitrate (GTN) induced
vasodilation were measured by forearm strain-gauge plethys- endothelial function [6–8]. Non-invasive measurements
mography, and von Willebrand (vW) antigen, plasma homocys- of endothelium-dependent vasodilation are commonly
teine (tHcy) and neurohormones were measured pre- and post- used, and have shown impaired responses in people withdialysis.
end-stage renal disease (ESRD) [9, 10]. Impaired vasodi-Results. Despite achieving target post-dialysis weights with
lation may lead to increased peripheral vascular resis-all treatments, pre-dialysis weight tended higher on SD. Endo-
thelial dependent vasodilation increased after all HD treat- tance and hypertension. Hypertension is very common
ments but did not differ between them. Adrenomedullin, in ESRD, except where long (8-hours) hemodialysis is
N-terminal brain natriuretic peptide and vW antigen increased used [11]. It is not clear whether the improved bloodsimilarly across all HD whereas atrial and C-type natriuretic
pressure associated with long hemodialysis is due solelypeptide, and endothelin-1 decreased across dialysis and were
to better control of body fluids or if other factors, suchhigher with SD. Pre-dialysis plasma tHcy concentrations were
13% higher during SD treatment. as improved endothelial function, also contribute [12].
Conclusion. Hemodialysis improved endothelial-dependent The aims of this study were, firstly, to determine the
vasodilation but the effect was similar with all three HD treat- effect of hemodialysis on endothelial-mediated vasodila-ments. Improved endothelial function might result in part from
tion, markers of endothelial injury, homocysteine andaltered local hormone production (endothelin-1 and adre-
vasoactive peptide hormones, and secondly, to ascertainnomedullin). These data suggest that increasing dialysis time is
unlikely, in the short-term, to significantly improve endothelial whether longer dialysis times impact differently on the
function in patients with end-stage renal disease, but longer endothelium. The hypothesis was that long dialysis causes
term studies are needed. greater improvement in endothelial function, which may
lead to better blood pressure control.
Key words: end-stage renal disease, hypertension, endothelium, adre-
nomedullin, nitric oxide, atrial natriuretic peptide.
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consent. Eight patients (6 male, all Caucasian) were re- remained caffeine-free and were given standard meals
at 0900 and 1200 hours.cruited. It was estimated from previous studies at this
institution and elsewhere [13, 14] that this number would
Strain-gauge plethysmographyallow detection of a 10% relative difference in endothe-
Subjects refrained from taking caffeine for 24-hourslium dependent vasodilation between treatments ( 
and attended at 0700 hours after a 16-hour overnight0.05,   0.8). The patients’ median (range) age was 56
fast. They lay supine for 30 minutes in a room that was(29 to 72) years and they had been on home hemodialysis
held at a constant temperature (22C). The hyperemicseven hours (6 to 8) three times weekly for a median of
response to forearm ischemia was assessed using an auto-15 months (6 to 132). Six patients had chronic glomerulo-
mated plethysmograph (E40; Hokanson, Seattle, WA,nephritis as the cause of their ESRD, one had obstructive
USA) by following the method described by Sax et alnephropathy and in one the cause was unknown. By
[15] and modified according to the guidelines of Playforddesign, none were taking antihypertensive drugs, lipid
and Watts [6]. Briefly, a mercury-filled strain gauge waslowering drugs, aspirin or folate supplements, none were
placed around the non-fistula forearm 8 cm distal to thesmokers or had clinical evidence of arterial disease, and
antecubital fossa. The position of the strain gauge wasall had well functioning native arteriovenous fistulae.
marked to ensure the same position with each test. A
wrist cuff was inflated to 200 mm Hg to occlude bloodStudy design
flow to the hand. After calibration of the plethysmo-This was a randomized, crossover controlled trial de-
graph, a second cuff positioned on the upper arm wassigned to compare the effects of three types of hemodial-
inflated to 40 mm Hg for 15 seconds while continuouslyysis on the endothelium:
recording output from the strain gauge. The resting fore-
arm blood flow (FBF) was calculated from the mean of• Treatment A: Four-hour hemodialysis using a low-
three resting blood flow recordings taken 5 secondsflux 1.7 m2 polysulfone dialyzer and a blood-pump
apart. The upper cuff was then inflated to 230 mm Hgof 350 mL/min.
to completely occlude blood flow to the forearm. After• Treatment B: Eight-hour hemodialysis using a low-
five minutes of forearm ischemia the cuff was rapidlyflux 1.0-m2 polysulfone dialyzer and a blood pump
deflated to 0 mm Hg, then immediately re-inflated to 40of 150 mL/min.
mm Hg, with measurements taken at 5 and 15 seconds
• Treatment C: Eight-hour hemodialysis using a low-
after cuff release to obtain the peak FBF post-ischemia.
flux 1.7-m2 polysulfone dialyzer and a blood pump After resting for a further five minutes to allow FBF to
of 250 mL/min. return to baseline levels, the patient was given 0.4 mg
trinitrate (GTN sublingually) and the FBF measured
All treatments were performed in a hospital dialysis after 2, 3 and 4 minutes. A previous study in sixteen
unit with the same dialysis machine (Fresenius 2000B; normal subjects found this technique to have a coefficient
Fresenius, Linz, Austria) and bicarbonate buffer (so- of variation of 6% [13]. The coefficient of variation for
dium 140 mmol/L, bicarbonate 24 mmol/L). Patients re- pre-dialysis FBF in the current patients was 5.5%.
ceived all treatments for one week. Dialysis was done on To ensure consistency, all plethysmography results
Friday, Monday and Wednesday (the “study dialysis”). were reported by a single observer in a blinded manner.
Patients then switched to another treatment until all All post-dialysis plethysmography was performed at 1800
three types were completed. The treatment sequence hours and all subjects were kept nil-by-mouth from 1300
(A, B, C or B, C, A, etc.) was randomly allocated. All hours. To determine whether changes in vascular reactiv-
six possible sequence combinations were used, with two ity were due to dialysis and not circadian influences,
allocated twice. Each patient’s dry-weight was known “control” plethysmography was repeated at 0700 and
and was kept as their target post-dialysis weight through- 1800 hours on a non-dialysis day.
out the study. Every eight-hour study dialysis ran from
Bioimpedance0800 to 1600 hours, while the four-hour dialyses ran from
1200 to 1600 hours to ensure that each treatment finished Total body water (TBW) predialysis was estimated by
at the same time. single frequency tetrapolar bioimpedance (BIM4; SEAC,
Queensland, Australia) using the formula of Kushner
Measurements and Schoeller [16]. Percentage TBW was calculated as
Weight (electronic scales) and blood pressure (mer- (TBW/target weight)  100.
cury sphygmomanometer) were measured before and 30
Blood samplesminutes after every dialysis. All other tests were done
only on study days, namely the third (Wednesday) dial- Blood was taken from the arterial fistula needle at the
start of each dialysis (0800 hours) and again one-hourysis of each treatment phase. On these days patients
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Table 1. Blood pressure, weight and selected blood values on study days (N  8)
Treatment
A-pre A-post B-pre B-post C-pre C-post
Systolic BPa 1549.8 1309.6 14910.2 13811.3 1529.5 1409.8
Diastolic BPb 893.9 795.8 833.8 765.9 853.9 795.8
Weightc kg 70.65.3 68.15.3 69.65.1 67.85.3 69.95.3 67.95.3
TBW L 58.86.8 — 57.36.4 — 57.25.9 —
eKt/V 1.160.1d — 1.520.05d — 2.480.11d —
Creatinine 0.960.1d — 0.830.09d — 0.760.06d —
Hematocrit 0.280.02 0.310.02 0.270.02 0.310.02 0.270.01 0.300.02
vWFc l/dL 1789.1 1999.7 17615.8 20513.5 18111.4 21618.4
tHcyb lmol/L 41.37.6d 27.26.1 35.97.7d 19.84.1 36.98.4d 17.94.6
Data are meanSEM. Abbreviations are: BP, blood pressure; TBW, total body water; eKt/V, dialysis dose; vWF, von Willebrand factor; tHcy, total homocysteine.
aP  0.05, bP  0.01 and cP  0.001 across dialysis
dP  0.001 in predialysis tHcy between treatments A and B or C
post-dialysis (1700 hours). Hematocrit was measured in RESULTS
duplicate by capillary centrifugation. The full blood count All eight patients completed the study and data collec-
(STKS; Coulter Electronics, Luton, UK) and serum bio- tion was complete. The eKt/V achieved with each treat-
chemistry and lipids (Aeroset, Abbott Diagnostics, North ment (A  B  C) was progressively higher and the
Chicago, IL, USA) were measured by routine automated corresponding pre-dialysis plasma creatinine lower (Ta-
ble 1). Albumin, calcium, phosphate, lipids and hemato-assays. Equilibrated Kt/V was calculated from the pre-
crit did not differ between treatments. Plasma viscositydialysis and one-hour post-dialysis urea concentrations,
(P  0.001) and von Willebrand antigen (P  0.001)using the formula of Daugirdas [17]. Plasma viscosity at
increased across dialysis but did not differ between treat-37C was measured in duplicate using a Harkness cap-
ments (Table 1). Plasma tHcy decreased by 34%, 44.8%illary viscometer (Coulter Electronics) [18]. Von Wille-
and 51.5% with treatments A, B and C, respectivelybrand antigen was measured by a sandwich enzyme-linked
(P  0.001 for all). Pre-dialysis tHcy was lower duringimmunosorbent assay (ELISA) using rabbit antibody
treatment A than with either B or C (P 0.001; Table 1).[19]. Fasting plasma total homocysteine (tHcy) concen-
trations were measured by a commercially available flu- Blood pressure
orescent polarizing immunoassay (IMX; Abbott). Mean pre- and post-dialysis blood pressures did not
differ significantly between the three HD treatments.
Neurohormones Post-dialysis weight was similar with all treatments, but
Blood samples were centrifuged immediately and the pre-dialysis weight was 0.7 to 1.0 kg higher on treatment
separated plasma frozen at 80C until analysis. Radio- A (P  0.08) and pre-dialysis TBW tended to be higher
immunoassay, using either commercially available or lo- (P  0.17; Table 1).
cally raised antisera, was used for measurements of atrial
Plethysmographynatriuretic peptide (ANP), brain natriuretic peptide (BNP),
The resting forearm blood flow was similar on all threeN-terminal (1-76) BNP (N-BNP), C-type natriuretic pep-
treatments pre-dialysis and it did not change significantlytide, adrenomedullin (ADM) [20–22] and endothelin-1
post-dialysis (Fig. 1). The increase in FBF following GTN[23]. All samples from an individual were analyzed in a
was similar pre- and post-dialysis, and did not changesingle assay to avoid interassay variability. Intra-assay
between treatments (Fig. 1). The peak FBF after fivecoefficients of variation were between 5 and 9%.
minutes of ischemia was 14.3 1.2 mL/min/100 mL tissue
pre-dialysis and 21.1  2.7 mL/min/100 mL post-dialysisStatistics
(P  0.005). The improvement in hyperemic response
Data were analyzed using SPSS statistical software. post-dialysis was similar with all three treatments (Fig.
Analysis of variance for repeated measures was used to 1). There was no change in resting, post-GTN or post-
compare the effects of the three treatments and changes ischemia FBFs between 0800 and 1800 on non-dialysis
across dialysis on each treatment. Possible confounding control days (data not shown).
effects of the treatment sequence were controlled for by
Neurohormonesusing all possible combinations. P values less than 0.05
were considered statistically significant. Data are shown Compared to treatments B and C, treatment A was
associated with significantly higher predialysis plasma con-as mean  SEM, unless otherwise stated.
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Fig. 2. Percentage of change in plasma neurohormone levels acrossFig. 1. Forearm blood flow at rest (), after sublingual GTN (),
dialysis. Symbols are: () adrenomedullin; () endothelin-1 (ET-1);and post-ischemia ( ). A, B and C refer to dialysis treatments (pre-
() C-type natriuretic peptide (CNP). Data are mean  SEM, andand post-dialysis measurements). aP  0.005 between peak hyperemic
are grouped from the three phases of the study. aP  0.05, bP  0.01.response pre- and post-dialysis (mean  SEM). There were no signifi-
cant differences in resting or post-GTN flows across dialysis or between
treatments.
Table 2. Changes in neurohormones with dialysis (N  8)
Treatment Ref. range A-pre A-post B-pre B-post C-pre C-post
ANPa pmol/L 4–27 98.322.5 48.911.0 77.822.1 46.211.7 58.314.7 48.214.1
BNPb pmol/L 3–12 46.711.7 43.611.2 37.69.9 34.49.5 33.125.4 33.98.8
N-BNPc pmol/L 2–50 302.589.4 353.0103.9 259.987.5 258.887.1 220.771.4 251.674.8
ET-1d pmol/L 0.9–2.3 3.690.23 3.390.23 3.420.24 3.230.23 3.360.21 3.150.21
AMe pmol/L 4–28 13.92.1 15.52.8 11.11.1 12.40.9 11.21.1 12.90.9
CNPf pmol/L 0–4 4.780.46 3.390.28 4.130.46 2.920.33 4.040.37 2.710.29
Data are meanSEM. Abbreviations are: ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; N-BNP, N-terminal (1-76) BNP; ET-1, endothelin-1;
CNP, C-type natriuretic peptide.
aP  0.05 across dialysis and between treatments
bP  0.05 between treatments
cP  0.05 across dialysis and between treatments
dP  0.001 across dialysis and P  0.05 between treatments
eP  0.05 across and between treatments
fP  0.01 across dialysis and P  0.01 between treatments
centrations of ANP (P 0.02), BNP (P  0.02), N-BNP lower with the eight-hour compared to the four-hour
dialysis, there was no difference in the hyperemic re-(P  0.037), CNP (P  0.01) and endothelin-1 (P 
sponse between the different forms of hemodialysis.0.016), whereas adrenomedullin was not significantly dif-
Numerous studies have used vasodilator responses asferent. Across dialysis, plasma ANP (P  0.02), CNP
an index of endothelial function in a variety of settings,(P  0.008) and endothelin-1 (P  0.006) all decreased,
but studies in hemodialysis patients are few and the re-whereas N-BNP (P  0.017) and adrenomedullin in-
sults conflicting. Miyazaki et al found that HD impairedcreased (P  0.013) and BNP was unchanged (Table 2,
endothelial function [24] and Kosch et al found that itFigs. 2 and 3).
had no effect [25]. In contrast, Cross et al found improve-
ment in flow-mediated dilation of the brachial artery
DISCUSSION with hemodialysis [14], while Hand et al [26] reported
In these HD patients endothelial function, as mea- that both hemodialysis and l-arginine increased acetyl-
sured by the vascular responsiveness to forearm isch- choline induced venodilation of dorsal hand veins. Asym-
emia, was improved by hemodialysis. Hemodialysis also metric dimethyl-arginine (ADMA), a known inhibitor
reduced plasma endothelin-1 (ET-1) levels and increased of nitric oxide synthase (NOS), has been shown to accu-
mulate in uremia and be cleared by dialysis [27–29].plasma adrenomedullin. Although ET-1 tended to be
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decreased across dialysis. Totsune et al [38] and Taka-
hashi et al [39] reported similar findings. Whereas CNP
is known to be secreted by, and act on, endothelial cells,
there have been few studies of CNP in ESRD patients
and the significance of these findings therefore is unclear.
The second objective of this study was to determine
whether long versus short hemodialysis times were asso-
ciated with improved endothelial function. If so, this may
have partly explained the superior BP control achieved
by long-slow hemodialysis [40] and the observation that
peripheral resistance is lower in these patients [41]. In
the event, the hypothesis was disproved (but note the
caveats later in this article). Although patients were dia-
lyzed to the same target weight and had the same post-
dialysis ANP levels with each treatment, their interdia-
Fig. 3. Percentage of change in plasma neurohormone levels across lytic weight gains tended to be higher during four-hourdialysis. Symbols are: () N-terminal (1-76) brain natriuretic peptide
dialysis accompanied by increases in plasma ANP, BNP(N-BNP); () brain natriuretic peptide (BNP); () atrial natriuretic
peptide (ANP). Data are mean  SEM, and are grouped from the and ET-1 concentrations. The small increase in ET-1,
three phases of the study. aP  0.05. associated with a small, sustained change in ECF volume,
may alter the balance of vasoconstrictor to vasodilator
hormones and over time lead to increases in peripheral
vascular resistance and blood pressure.
Nitric oxide (NO) production by endothelial cells deter- To our knowledge, this is the first study to show that
mines the vasodilation response and it is presumably increasing the dialysis time decreases plasma tHcy con-
augmented by adding substrate for NO synthesis (l-argi- centrations. Van Tellingen et al recently showed that
nine) or by removing endogenous inhibitors, such as plasma tHcy concentrations could be lowered by high
ADMA, with dialysis [26]. flux dialysis [42]. Homocysteine is an independent risk
The improved endothelium dependent vasodilation factor for cardiovascular complications in ESRD [43] and
observed post-dialysis in our patients occurred alongside increases in plasma tHcy have been shown to cause acute
a decrease in ET-1 and an increase in adrenomedullin endothelial dysfunction [44, 45]. The decrease in tHcy
(AM) concentrations. Both peptides are secreted by en- with dialysis may have contributed to improved endothe-
dothelium [30, 31] and have autocrine/paracrine actions, lial responses post-dialysis, but whether the modest de-
but they have contrasting effects on vascular tone. Endo- crease in predialysis tHcy concentrations achieved dur-
thelin-1 is a powerful vasoconstrictor [32], whereas AM ing long dialysis is of any clinical significance is uncertain.
is a potent vasodilator that is, in part, nitric oxide depen- The main limitation of this study was that each treat-
dent [33]. Circulating ET-1 is increased in ESRD [30], ment was administered for only one week. This was done
but studies of the effect of hemodialysis on ET-1 levels for reasons of logistics and cost, but it may have been
are contradictory as some show ET-1 is increased by insufficient time to allow significant changes in endothe-
dialysis [34] while others show it is decreased [35]. Malla- lial function to occur. The crossover study design and
maci et al found that AM decreased with isolated ultra- use of all combinations of treatment sequence meant
filtration [36], whereas Washimine et al found no change that physiologically significant changes should have been
in AM levels across dialysis [37]. These variable results detected. Blood pressure did not differ significantly be-
may reflect the effect of different dialysis membranes. tween treatments, however, and we cannot discount the
In the current patients, hemodialysis consistently caused possibility that carryover effects may have prevented
a decrease in ET-1 (molecular weight  2492) and an in- differences in endothelial function from being observed.
crease in AM (molecular weight 6029) levels, changes It also is possible that small differences in endothelial
that may have been the result of different dialyzer clear- function occurred but were not detectable with this num-
ances. These changes may have contributed to the im- ber of participants. Whereas all methods of assessing
proved endothelial responses after hemodialysis. Although endothelial function are operator dependent, observer
the changes in ET-1 and AM concentrations were small, error was minimized by having a single observer interpret
they were statistically significant and might reflect a many- all plethysmography data in a blinded fashion.
fold greater change in hormone concentrations within In summary, hemodialysis caused a temporary im-
vascular smooth muscle cells. provement in endothelial dependent vasodilation, which
C-type natriuretic peptide concentrations were ele- may have been due in part to a reduction in plasma ET-1
and tHcy, and an increase in adrenomedullin concentra-vated above the reference range pre-dialysis and they
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pool variable volume Kt/V: An analysis of error. J Am Soc Nephroltions across hemodialysis. Compared to four-hour dial-
4:1205–1213, 1993
ysis, eight-hour dialysis was associated with less interdia- 18. Harkness J: The viscosity of human plasma, its measurement in
lytic weight gain and lower levels of the natriuretic health and disease. Biorheology 8:171–193, 1971
19. Short PE, Williams CE, Picken AM, Hill FG: Factor VIII relatedpeptides and ET-1, but no discernible change in endothe-
antigen: An improved enzyme immunoassay. Med Lab Sci 39:351–lial dependent vasodilation. This study suggests that, in 355, 1982
the short-term, increasing the dialysis time is unlikely to 20. Lainchbury JG, Nicholls MG, Espiner EA, et al: Bioactivity and
interactions of adrenomedullin and brain natriuretic peptide inalter endothelial function in patients receiving hemodial-
patients with heart failure. Hypertension 34:70–75, 1999ysis, but longer-term studies are needed. 21. Hunt PJ, Richards AM, Nicholls MG, et al: Immunoreactive
amino-terminal pro-brain natriuretic peptide (NT-PROBNP): A
new marker of cardiac impairment. Clin Endocrinol (Oxf) 47:287–ACKNOWLEDGMENTS
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